Cantargia presents unique effects of nadunolimab in pancreatic cancer
Cantargia today presented new preclinical data for its lead candidate, the IL1RAP-binding antibody nadunolimab at the AACR Annual Meeting. The data show that nadunolimab targets a fundamental...
Source: marketscreener.com